Bangladess - enska - DGDA (Directorate General of Drug Administration)

save pharmaceuticals ltd. - cyanocobalamin + pyridoxine hydrochloride + vitamin b1 - tablet - 200 mcg + 200 mg + 100 mg

Bangladess - enska - DGDA (Directorate General of Drug Administration)

save pharmaceuticals ltd. - aceclofenac - tablet - 100 mg

Bangladess - enska - DGDA (Directorate General of Drug Administration)

save pharmaceuticals ltd. - fluconazole - capsule - 50 mg

Bangladess - enska - DGDA (Directorate General of Drug Administration)

save pharmaceuticals ltd. - fluconazole - capsule - 150 mg

Bangladess - enska - DGDA (Directorate General of Drug Administration)

save pharmaceuticals ltd. - calcium (coral calcium) + vitamin d3 - tablet - 500 mg + 200 iu

Bangladess - enska - DGDA (Directorate General of Drug Administration)

save pharmaceuticals ltd. - esomeprazole - capsule - 40 mg

Bangladess - enska - DGDA (Directorate General of Drug Administration)

save pharmaceuticals ltd. - caffeine + paracetamol - tablet - 65 mg + 500 mg

Singapúr - enska - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - dexlansoprazole - capsule, delayed release - 30mg - dexlansoprazole 30mg

Singapúr - enska - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - dexlansoprazole - capsule, delayed release - 60mg - dexlansoprazole 60mg

Evrópusambandið - enska - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - docetaxel - stomach neoplasms; adenoma; breast neoplasms; carcinoma, non-small-cell lung; prostatic neoplasms - antineoplastic agents - breast cancerdocetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancerdocetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancerdocetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinomadocetaxel in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancerdocetaxel in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.